Triamcinolone acetate

Phase 1Small molecule

BBrixton Biosciences, Inc.

Triamcinolone acetate is one of 65 small molecule programs targeting Osteoarthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

Greater Trochanteric Pain SyndromeNot yet recruiting

Age-Related Macular DegenerationActive, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

Greater Trochanteric Pain SyndromePreclinical

Not yet recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Glucophage

Boehringer Ingelheim

Preclinical

1 6

Paracetamol

GSK

Preclinical

4 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Lunesta

Akero Therapeutics

Preclinical

1 9

Ansaid

PPharmacia and Upjohn

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/AActive, not recruiting

Osteoarthritis

NCT06700109

Q4 2029

PreclinicalNot yet recruiting

Greater Trochanteric Pain Syndrome

NCT07568015

Clinical

Trials by Indication[1]

Diabetic Macular Oedema3 trials

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

Completed·UUniversity of Sydney·Phase 2/3·NCT00167518·70 enrolled

A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema

Completed·UUniversity of Sydney·Phase 2/3·NCT00148265·54 enrolled

Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

Completed·UUniversity of Sydney·Phase 2/3·NCT00148330·64 enrolled

MCI1 trial

Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Unknown status·—·Phase 2/3·NCT04460001·100 enrolled

Osteoarthritis1 trial

INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE

Active, not recruiting·BBrixton Biosciences, Inc.·N/A·NCT06700109·263 enrolled

Age-Related Macular Degeneration1 trial

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Completed·MManhattan Eye, Ear & Throat Hospital·Phase 1·NCT00211419

Greater Trochanteric Pain Syndrome1 trial

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain: A Multi-Center, Randomized, Controlled Trial (RENEU)

Not yet recruiting·BBrixton Biosciences, Inc.·Preclinical·NCT07568015·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Triamcinolone acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triamcinolone acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triamcinolone acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brixton Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBrixton Biosciences, Inc.

Triamcinolone acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Trials by Indication[1]

Diabetic Macular Oedema3 trials

MCI1 trial

Osteoarthritis1 trial

Age-Related Macular Degeneration1 trial

Greater Trochanteric Pain Syndrome1 trial

References

Drug Info

Quick Facts

Related News